Karyopharm Therapeutics Inc
NASDAQ:KPTI
Intrinsic Value
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatmen... [ Read More ]
The intrinsic value of one
KPTI
stock under the Base Case scenario is
6.563
USD.
Compared to the current market price of 1.155 USD,
Karyopharm Therapeutics Inc
is
Undervalued by 82%.
Karyopharm Therapeutics Inc's market capitalization is 132.7m USD.
KPTI stock price is 1.155 USD.
KPTI stock price (1.155 USD) is 82% less than its Intrinsic Value (6.563 USD).
KPTI. Open DCF Valuation
KPTI stock price (1.155 USD) is 82% less than its Relative Value (6.563 USD). Open Relative Valuation
KPTI has upside potential of 392% compared to the average analyst price target.
Open Wall St Estimates
KPTI has positive Net Debt. This means that the company has more debt (303m USD) than cash and short-term investments (191m USD).
KPTI's Revenue has dropped by 7% over the past 12 months.
KPTI's Revenue has been growing by 11% per year for the last 3 years.
KPTI's Revenue is forecast to grow at a rate of 17% per year over the next 3 years.
KPTI's ROE (Return on Equity) has significantly increased in the last 3 years from -317% to 187%.
KPTI's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -323% to -211%, and is approaching profitability.
KPTI's long-term liabilties (377m USD) exceed its long-term assets (240m USD).
KPTI has negative Operating Income for the last twelve months.
KPTI has negative Net Income for the last twelve months.
KPTI's ROE (Return on Equity) for the past 12 months is very high and is equal to 187%.
KPTI's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -211%.
KPTI has positive Gross Profit for the last twelve months.
KPTI has negative Free Cash Flow for the last twelve months.
KPTI's short-term assets (234m USD) exceed its short-term liabilties (69m USD).
KPTI has very high three-year average ROE (Return on Equity): 124%. The company is very efficient at transforming stockholders' equity into net income.
KPTI has negative three-year average ROIC (Return on Invested Capital): -208%. The company is not efficient at using invested capital to generate operating income.
KPTI's D/E (Debt to Equity) is very low and is equal to -2.23.
KPTI's Altman Z-Score is very low and is equal to -9.81.
KPTI doesn't generate enough operating income (-130m USD) to safely cover interest payments on its debt (5m USD).
Valuation Backtest
Karyopharm Therapeutics Inc
Run backtest to discover the historical profit from buying and selling
KPTI
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Karyopharm Therapeutics Inc
Balance Sheet Decomposition
Karyopharm Therapeutics Inc
| Current Assets | 233.9m |
| Cash & Short-Term Investments | 191.4m |
| Receivables | 27m |
| Other Current Assets | 15.5m |
| Non-Current Assets | 6.5m |
| PP&E | 4.9m |
| Other Non-Current Assets | 1.6m |
| Current Liabilities | 69.5m |
| Accounts Payable | 3.1m |
| Accrued Liabilities | 64.7m |
| Other Current Liabilities | 1.7m |
| Non-Current Liabilities | 307.2m |
| Long-Term Debt | 303.4m |
| Other Non-Current Liabilities | 3.8m |
Earnings Waterfall
Karyopharm Therapeutics Inc
|
Revenue
|
146m
USD
|
|
Cost of Revenue
|
-4.9m
USD
|
|
Gross Profit
|
141.1m
USD
|
|
Operating Expenses
|
-270.6m
USD
|
|
Operating Income
|
-129.5m
USD
|
|
Other Expenses
|
-13.6m
USD
|
|
Net Income
|
-143.1m
USD
|
Free Cash Flow Analysis
Karyopharm Therapeutics Inc
What is Free Cash Flow?
KPTI Profitability Score
Profitability Due Diligence
Karyopharm Therapeutics Inc's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
Score
Karyopharm Therapeutics Inc's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
KPTI Solvency Score
Solvency Due Diligence
Karyopharm Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Karyopharm Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
KPTI Price Targets Summary
Karyopharm Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
KPTI
is 5.683 USD
with a low forecast of 3.03 USD and a high forecast of 8.4 USD.
Ownership
KPTI Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
KPTI Price
Karyopharm Therapeutics Inc
| Average Annual Return | 36.15% |
| Standard Deviation of Annual Returns | 155.02% |
| Max Drawdown | -98% |
| Market Capitalization | 132.7m USD |
| Shares Outstanding | 115 067 000 |
| Percentage of Shares Shorted | 20.29% |
Company Profile
Karyopharm Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company is headquartered in Newton Center, Massachusetts and currently employs 442 full-time employees. The company went IPO on 2013-11-06. The firm is focused on the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (CRM1). Its lead compound, XPOVIO (selinexor), is marketed in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). NEXPOVIO (selinexor), the brand name for XPOVIO in Europe and the United Kingdom, in combination with dexamethasone to treat adult patients with multiple myeloma.
Contact
IPO
Employees
Officers
The intrinsic value of one
KPTI
stock under the Base Case scenario is
6.563
USD.
Compared to the current market price of 1.155 USD,
Karyopharm Therapeutics Inc
is
Undervalued by 82%.
You don't have any saved screeners yet
